Autoinduction of MKC-963 [(R)-1-(1-cyclohexylethylamino)-4- phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 950-954

  Shimizu, Toshiyuki ^a,c   Akimoto, Kei ^a   Yoshimura, Takuya ^a   Niwa, Takuro ^a   Kobayashi, Kaoru ^c   Tsunoo, Michio ^b   Chiba, Kan ^c  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b KITASATO INSTITUTE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYCLOHEXYLEHTYLAMINO) 4 PHENYLPHTHALAZINE; 6BETA HYDROXYHYDROCORTISONE; ANTITHROMBOCYTIC AGENT; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 3A4; HYDROCORTISONE; MESSENGER RNA; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; ENZYME INDUCTION; HORMONE ACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AGED; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; HYDROCORTISONE; HYDROXYTESTOSTERONES; MALE; PHTHALAZINES; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RNA, MESSENGER; TREATMENT FAILURE;

EID: 33646801604     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007997     Document Type: Article

References (29)

1. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554-563.
2. Donato MT, Castell JV, and Gómez-Lechón MJ (1995) Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos 23:553-558.
3. Donato MT, Herrero E, Gómez-Lechón MJ, and Castell JV (1993) Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol In Vitro 7:481-485.
4. Galteau MM and Shamsa F (2003) Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733.
5. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
6. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
7. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
8. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
9. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
10. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
11. Jerling M, Huan BL, Leung K, Chu N, Abdallah H, and Hussein Z (2005) Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 45:422-433.
12. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Investig 90:1871-1878.
13. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, and Jorkasky DK (1998) Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 63:617-622.
14. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Investig 102:1016-1023.
15. Li AP, Kaminsky DL, and Rasmussen U (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
16. Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, and Kobayashi T (1990) Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. Cancer Chemother Pharmacol 27:20-26.
17. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
18. Ohnhaus EE, Breckenridge AM, and Park BK (1989) Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36:39-46.
19. Prueksaritanont T, Ma B, and Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A and not CYP2D6. Br J Clin Pharmacol 56:120-124.
20. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, and Sunbhanich M (2002) Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 72:505-513.
21. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping. Biochem Pharmacol 57:465-480.
22. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, and Sinz MW (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439-446.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
24. Smith DA (2000) Induction and drug development. Eur J Pharm Sci 11:185-189.
25. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, and Martin DE (1999) Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 39:487-494.
26. Villikka K, Kivistö KT, and Neuvonen PJ (1999) The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 65:377-381.
27. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Investig 80:1029-1036.
28. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
29. Zhuo X, Zheng N, Felix CA, and Blair LA (2004) Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos 32:993-1000.